Wendy's Rejects Trian Buyout Bid, Adopts Poison Pill
Wendy's rejected a $1.4 billion buyout offer from Nelson Peltz's Trian Fund Management on Thursday. The board also adopted a poison pill plan to deter a hostile takeover.
- $7.35 per share was the offer; stock traded at $7.75 Thursday premarket.
- 15% ownership by any person or group triggers the rights plan.
- 16.3% of shares are held by Trian and its partners.
- Flynn Group, BlueFive Capital and Sixth Street Partners joined Trian's bid.
Why it matters: The rejection keeps Wendy's betting on Wright's turnaround as sales and market share slip. Peltz argued a private sale was shareholders' best path in a tough fast-food market.
- 10.4% of U.S. burger chain sales went to Wendy's last year, down from 11.5%.
- 240 restaurants closed in 2024; up to 358 more are slated for 2026.
- Meritage, a franchisee with 314 Wendy's locations, filed for bankruptcy in September.
How 8 sources split on this story
Where they split: Outlets largely agree on the facts; the difference is emphasis, between the chain's long decline and its management's case for a standalone recovery.
Center coverage, 3 sources: The center frames it as a takeover fight set against Wendy's long competitive slide and store closures.
Left coverage, 4 sources: The left frames it as a board defending a profitable but slowing chain, with stress on inflation squeezing lower-income customers.
Right coverage, 1 sources: The right frames it as a billionaire's bid for a chain with a 70% six-year stock drop and a history of Peltz takeover attempts.
What’s next: The rights plan runs for one year, limiting Trian's ability to buy more shares. Trian did not immediately comment on the rejection.
- Wright says he will rebuild the menu and its pricing structure.
- Will Trian raise its offer or pursue a proxy fight?
- Can Wright's turnaround reverse the falling sales and market share?
- How will Bradley Peltz's dual role as board member and franchisee affect the dispute?
